Ad hoc release

Ad-hoc Release pursuant to Section 15 of the German Securities Trading Act (Wertpapierhandelsgesetz)

FDA grants approval for Ameluz® in the USA

Leverkusen, Germany, May 11, 2016 – Biofrontera AG (FSE: B8F), the specialist for sun-induced skin cancer, has received unconditional approval for marketing in the US from the Food and Drug Administration FDA for its prescription drug Ameluz® in combination with the PDT-lamp BF-RhodoLED® for the lesion-directed and field-directed treatment of mild to moderate actinic keratoses on the face and the scalp. FDA has not requested any post-approval obligations.

Further details shall be disclosed in a separate announcement shortly.

Leverkusen, May 11, 2016

The Management Board

Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen
ISIN: DE0006046113
WKN: 604611

contact: Biofrontera AG
Tel.: +49 (0214) 87 63 2 0, Fax.: +49 (0214) 87 63 290
e-mail: press@biofrontera.com